Literature DB >> 19822048

Osteoporosis in rheumatoid arthritis and ankylosing spondylitis.

D Vosse1, K de Vlam.   

Abstract

Bone is a target in many inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). The generalized effect of inflammation on bone may result in a decreased quality of bone and is associated with an increased risk of fractures and deformities, both in RA and AS. RA is characterized by periarticular osteopenia, systemic osteoporosis and bone erosions. Periarticular osteopenia and bone erosions are mainly correlated with disease activity. Unlike postmenopausal osteoporosis, osteoporosis in RA is more characterised by marked loss of bone in the hip and the radius, while the axial bone is relatively preserved. In general, several cross-sectional studies documented a lower bone mineral density in patients with RA, with a two-fold increase in osteoporosis compared to age- and sex-matched controls and relates to an increased fracture risk. Several factors contribute to the increased risk: older age, little exercise, long-term use of corticosteroids, and high disability index. AS is characterized by an increase in bone fragility due to reduced bone mineral density. The reported prevalence of osteoporosis in AS patients varies largely. The large variation reflects the difficulties in assessing BMD in AS due to new bone formation. Bone fragility is also due to changes in structural properties resulting from inflammation-induced bone failure in the spine in combination with reduced capacity of shock absorption leading to vertebral fractures. Different types of spinal fractures in patients with AS are described, including wedging. Wedging vertebral fractures contribute to hyperkyphosis and impaired physical function. In contrast to RA , bone loss in AS is accompanied by new bone formation. The pathophysiology of osteoporosis in RA and AS probably is fundamentally similar, but with different clinical phenotypes. The implications for therapeutically intervening in its occurrence and progression might be fundamentally different.

Entities:  

Mesh:

Year:  2009        PMID: 19822048

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  24 in total

Review 1.  Advances in the medical treatment of rheumatoid arthritis.

Authors:  J Michelle Kahlenberg; David A Fox
Journal:  Hand Clin       Date:  2011-02       Impact factor: 1.907

2.  Bilateral synchronous total hip arthroplasty for ankylosed hips.

Authors:  He Bangjian; Tong Peijian; Li Ju
Journal:  Int Orthop       Date:  2011-07-13       Impact factor: 3.075

3.  Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.

Authors:  Y E Chung; S H Lee; S-Y Lee; S-Y Kim; H-H Kim; F S Mirza; S-K Lee; J A Lorenzo; G S Kim; J-M Koh
Journal:  Osteoporos Int       Date:  2011-06-10       Impact factor: 4.507

4.  Prevalence and associated factors of osteoporosis in female patients with rheumatoid arthritis.

Authors:  Maryam Mobini; Zahra Kashi; Asieh Ghobadifar
Journal:  Caspian J Intern Med       Date:  2012

5.  Inhibition of osteoclast differentiation and matrix metalloproteinase production by CD4+CD25+ T cells in mice.

Authors:  P T Yang; X H Meng; Y Yang; W G Xiao
Journal:  Osteoporos Int       Date:  2012-05-23       Impact factor: 4.507

6.  Exercise capacity independently predicts bone mineral density and proximal femoral geometry in patients with acute decompensated heart failure.

Authors:  J-C Youn; S J Lee; H S Lee; J Oh; N Hong; S Park; S-H Lee; D Choi; Y Rhee; S-M Kang
Journal:  Osteoporos Int       Date:  2015-05-12       Impact factor: 4.507

7.  Rheumatoid arthritis patients with hip fracture: a nationwide study.

Authors:  Y-C Lin; Y-H Li; C-H Chang; C-C Hu; D W Chen; P-H Hsieh; M S Lee; S W-N Ueng; Y Chang
Journal:  Osteoporos Int       Date:  2014-11-20       Impact factor: 4.507

8.  Incidence and risk factors for vertebral fracture in rheumatoid arthritis: an update meta-analysis.

Authors:  Yang Liu; Jun Jiang; Minmin Mo; Xiaohong Sun; Kailong Yu
Journal:  Clin Rheumatol       Date:  2022-01-10       Impact factor: 2.980

9.  Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.

Authors:  J-P Roussy; L Bessette; S Bernatsky; E Rahme; J Lachaine
Journal:  Osteoporos Int       Date:  2013-03-16       Impact factor: 4.507

10.  Prevalence and risk factors associated with vertebral osteoporotic fractures in patients with rheumatoid arthritis.

Authors:  Jing-Jing Tong; Sheng-Qian Xu; He-Xiang Zong; Mei-Juan Pan; Yu-Zhu Teng; Jian-Hua Xu
Journal:  Clin Rheumatol       Date:  2019-11-05       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.